<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70505">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918241</url>
  </required_header>
  <id_info>
    <org_study_id>JY062013B</org_study_id>
    <nct_id>NCT01918241</nct_id>
  </id_info>
  <brief_title>Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia</brief_title>
  <acronym>PEG-rhG-CSF</acronym>
  <official_title>Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Jiuyuan Gene Engineering Co. Ltd.,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, CAMS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LIN YI TUMOUR HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Jiuyuan Gene Engineering Co. Ltd.,</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a
      single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Duration of ≥grade 3 neutropenia in cycle 2</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of Neutropenia and ANC in cycle 2</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of ≥grade 3 neutropenia;
Incidence of febrile neutropenia;
Measurement the duration from chemotherapy finished to the ANC reached the nadir and the value of ANC`s nadir;
Time to ANC recovery,the time from chemotherapy administration  until the patient`s ANC increasd to 2.0*109/L after the expected nadir</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>pegfilgrastim,30mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pegfilgrastim, 60mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pegfilgrastim,100mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>filgrastim,5mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim,30mcg/kg</intervention_name>
    <description>Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.</description>
    <arm_group_label>pegfilgrastim,30mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim, 60mcg/kg</intervention_name>
    <description>Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.</description>
    <arm_group_label>pegfilgrastim, 60mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim, 100mcg/kg</intervention_name>
    <description>Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.</description>
    <arm_group_label>pegfilgrastim,100mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim, 5mcg/kg</intervention_name>
    <description>At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.</description>
    <arm_group_label>filgrastim,5mcg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-70 years；

          -  Comfirmed advanced tumor patients by histopathological with regarding
             initialtreatment or adjuvant, or neoadjuvant chemotherapy,suitable for chemotherapy
             with canboplatin combined with taxol or cyclophosphamide combined with pharmorubicin
             in the opinion of the investigator；

          -  Performance status（EOCG）≤1；

          -  Normal human peripheral blood are eligible for the chemotherapy, WBC≥3,500 per cubic
             millilit, ANC ≥ 1,500 per cubic milliliter, PLT ≥ 100,000 per cubic milliliter；

          -  Normal ECG examination；

          -  Without liver metastasis patients: the level of ALT、TBIL、AST were in the 2.5 times of
             upper normal limit; Liver metastasis patients: the level of ALT、TBIL、AST were in the
             5 times of upper normal limit;

          -  Renal function indices：the level of Cr、BUN were bothe in the 1.25 times of upper
             normal limit;

          -  Life expectancy ＞3 months;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Be treated with radiotherapy in nearly 4 weeks(not included local radiotherapy for
             the bone metastasis);

          -  Be treated with hemopoietic stem cell transplantation or bone marrow transplant；

          -  Not adequately controlled infections(e.g. ANC ≥ 12,000 per cubic
             milliliter,temperature &gt; 38.2℃)

          -  Evidence of metastatic disease in bone marrow,or with other malignant tumors （not
             included cured basal cell carcinoma and endometrial carcinoma）；

          -  Subjects with unconscious or symptomatic brain metastases；

          -  Subjects with serious heart、liver and renal disease;

          -  Subjects with serious diabetes or poor control in glycemia;

          -  Pregnant or breast-feeding period females;

          -  Be treated with  antibiotics in 72 hours or currently being treated with antibiotics;

          -  Treated with PEG-rhG-CSF in past;

          -  Participated 3 or more than 3 clinical trials in nearly a year(as subjects) or any
             clinical trials in nearly 3 months;

          -  Allergic disorders or allergies subjects or known hypersensitivity to filgrastim or
             any of the products to be administered during dosing;

          -  Suspected or comfirmed evidences of drug、treatment of drugs or alcohol abused;

          -  Serious Neurological disorders that would affect the consent or observation;

          -  Other conditions which in the opinion of the investigator preclude enrollment into
             the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Qin, M.D.</last_name>
    <phone>010-8778-8507</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegylation</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Satety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
